loader from loading.io

#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

The Peter Attia Drive

Release Date: 07/13/2026

#412 ‒ The evolving science of cancer: emerging approaches to prevention and early detection, and the advances reshaping treatment | Siddhartha Mukherjee, M.D., Ph.D. show art #412 ‒ The evolving science of cancer: emerging approaches to prevention and early detection, and the advances reshaping treatment | Siddhartha Mukherjee, M.D., Ph.D.

The Peter Attia Drive

In this episode, Peter welcomes back Dr. Siddhartha Mukherjee, a physician, oncologist, researcher, and the Pulitzer Prize-winning author of The Emperor of All Maladies. Fifteen years after the book was first published, Sid released an updated edition. This conversation examines what has changed in our understanding of cancer—not only in how we treat it, but in how we think about its causes, prevention, detection, and biology. Sid explores the contributions of genetics, environmental exposures, random mutations, and inflammation to cancer risk, including the emerging role of...

info_outline
#411 ‒ AMA #90: Strong convictions, loosely held: how Peter’s views on fasting, keto, metformin, rapamycin, whole-body MRI, and exercise have changed show art #411 ‒ AMA #90: Strong convictions, loosely held: how Peter’s views on fasting, keto, metformin, rapamycin, whole-body MRI, and exercise have changed

The Peter Attia Drive

In this “Ask Me Anything” (AMA) episode, Peter looks back on 400 episodes of The Drive with another installment of “strong convictions, loosely held,” revisiting some of the positions he has taken over more than eight years of the podcast. He explains why changing one’s mind in response to new evidence, conversations with experts, and clinical experience is essential for practicing medicine well. Peter begins with nutrition, describing how his views on ketogenic diets, extended fasting, and the framework of dietary restriction, time restriction, and calorie restriction have...

info_outline
#410 ‒ The biology of pregnancy: physiologic adaptation, gestational diabetes, preeclampsia, childbirth, and long-term maternal health | Kathryn Gray, M.D., Ph.D. show art #410 ‒ The biology of pregnancy: physiologic adaptation, gestational diabetes, preeclampsia, childbirth, and long-term maternal health | Kathryn Gray, M.D., Ph.D.

The Peter Attia Drive

In this episode, Peter sits down with Dr. Kathryn (Katie) Gray, a physician-scientist, high-risk obstetrician, and maternal-fetal medicine specialist at the University of Washington School of Medicine. Katie begins by explaining the remarkable physiologic changes that occur during pregnancy and how the cardiovascular, metabolic, and hormonal systems adapt to support both mother and developing fetus. From there, the conversation turns to some of the most important complications that can arise. Katie explains how gestational diabetes is screened for and treated, and what a diagnosis may mean...

info_outline
#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D. show art #409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.

The Peter Attia Drive

Lloyd B. Klickstein is a physician-scientist who has spent more than 20 years at the intersection of drug discovery, healthy aging, and preventive medicine. Drawing on his experience in academic medicine, translational research, and biotechnology, Lloyd walks through the full arc of modern drug development. He explains how scientists identify an unmet medical need and decide which diseases and therapeutic targets are worth pursuing. From there, he takes us through the process of engineering a drug, testing it in animals, and navigating clinical trials and regulatory approval. Using...

info_outline
#408 ‒ AMA #89: Thyroid health: interpreting symptoms, diagnosing and treating dysfunction, and navigating the gray zone show art #408 ‒ AMA #89: Thyroid health: interpreting symptoms, diagnosing and treating dysfunction, and navigating the gray zone

The Peter Attia Drive

In this "Ask Me Anything" (AMA) episode, Peter takes a deep dive into thyroid health and explains why diagnosing and managing thyroid dysfunction is unusually complex. He begins with the basic biology of the thyroid gland and three commonly measured hormones—free T4, free T3, and TSH. He explains how T4 is converted to the active hormone T3 and the important functions T3 performs throughout the body. He also explains what reverse T3 is and when it may be useful to measure it. Peter then breaks down thyroid blood tests and their limitations and provides a practical framework for evaluating...

info_outline
#407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D. show art #407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

The Peter Attia Drive

Michael Davidson is a world-renowned cardiologist, lipidologist, and the founding CEO of NewAmsterdam Pharma. He begins this episode by sharing how his family history shaped his interest in lipidology and primary prevention. He explains why prevention should focus on causal drivers of disease rather than near-term risk and examines the causal relationship between LDL and atherosclerotic cardiovascular disease. Michael then traces the complicated history of CETP inhibitors—from the original rationale that raising HDL would reduce cardiovascular risk to the failures of torcetrapib,...

info_outline
Blood pressure: how to measure, manage, and treat high blood pressure (AMA #48 rebroadcast) show art Blood pressure: how to measure, manage, and treat high blood pressure (AMA #48 rebroadcast)

The Peter Attia Drive

In this “Ask Me Anything” (AMA) episode, Peter delves into the critical subject of blood pressure, which is one of the three primary causes of atherosclerosis, along with high apoB and smoking. He begins by unraveling the nature of high blood pressure, its prevalence, and why it often goes undiagnosed. Peter describes in detail the proper way to accurately measure blood pressure and what determines a diagnosis. Next, Peter discusses the actionable steps one can take in response to high blood pressure, shedding light on the extent to which factors like weight loss, exercise, and...

info_outline
#406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment | Brian Grosberg, M.D. show art #406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment | Brian Grosberg, M.D.

The Peter Attia Drive

Brian Grosberg is a world-renowned headache specialist who joins Peter to provide a master class on the diagnosis and treatment of headache disorders. In this episode, Brian explains the distinction between primary and secondary headaches and breaks down the defining features of the "big three" primary headache types (migraine, cluster, and tension headache)—highlighting how often they are misdiagnosed and how they are treated. He explores the epidemiology of headaches, describing migraine as an invisible disease affecting about 12% of the population, disproportionately affecting women,...

info_outline
#405 ‒ AMA #88: Metabolic liver health: how to assess risk, catch dysfunction early, and prevent or reverse liver disease show art #405 ‒ AMA #88: Metabolic liver health: how to assess risk, catch dysfunction early, and prevent or reverse liver disease

The Peter Attia Drive

In this "Ask Me Anything" (AMA) episode, Peter takes a deep dive into the liver and its central role in metabolic health. He explains why the liver can serve as a "canary in the coal mine" for metabolic dysfunction and explores how insulin resistance, visceral fat, alcohol consumption, genetics, and hormones contribute to liver disease, along with how increasing muscle mass can benefit liver health. Peter provides a framework for understanding the progression of liver disease, highlighting which stages are reversible and why early detection matters. He explains why normal liver enzymes can...

info_outline
#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D. show art #404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.

The Peter Attia Drive

In this episode, Peter sits down with Dr. Linus Abrams, a psychiatrist with nearly 35 years of clinical experience specializing in mood disorders and psychopharmacology, to explore how our understanding of mental health is evolving beyond the traditional neurotransmitter model. After decades in practice, Linus began questioning many of the assumptions underlying modern psychiatry, leading him to investigate how hormones, metabolism, inflammation, circadian biology, and the endocrine system shape mood and cognition. Together, Peter and Linus examine why psychiatric care should aim not only...

info_outline
 
More Episodes

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter’s Weekly Newsletter

Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer’s disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer’s disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care.

We discuss:

  • Gayatri’s training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45];
  • How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15];
  • The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30];
  • Gayatri’s comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45];
  • Why forgetting names is usually normal and when word-finding problems become concerning [29:00];
  • Why women are at higher risk for Alzheimer's disease and how menopause influences cognition [33:45];
  • The promise and limitations of blood-based biomarkers for diagnosing Alzheimer's disease [40:15];
  • When preclinical Alzheimer's screening is appropriate and how to interpret positive biomarker results [45:00];
  • Case study: early Alzheimer's prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15];
  • Anti-amyloid therapies: balancing clinical benefit with ARIA risk using slow titration [51:45];
  • The aducanumab controversy, why it was discontinued, and why Gayatri would still choose it [1:00:00];
  • How anti-amyloid therapies cause ARIA, strategies for detecting and managing these complications, and how future therapies may improve safety and accessibility [1:03:30];
  • Two patient examples of exceptional responses to anti-amyloid therapy [1:12:30];
  • A multimodal approach to Alzheimer's treatment: combination therapy, MRI-guided TMS, GLP-1 receptor agonists, and more [1:15:00];
  • Vascular dementia, Lewy body dementia, and the overlap with Alzheimer's disease [1:21:00];
  • Lewy body dementia and Parkinson's disease: distinguishing two alpha-synuclein disorders [1:26:45];
  • Risk factors for Lewy body dementia and what remains unknown [1:36:15];
  • Treating menopause-related cognitive impairment: hormone therapy, brain rehabilitation, and balancing breast cancer risk [1:38:45];
  • How biomarkers changed Gayatri's perspective on the potential for Alzheimer's patients to improve [1:47:15];
  • The future of Alzheimer's care: AI, precision medicine, and personalized treatment [1:49:30]; and
  • More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube